Market closed
XBiotech/$XBIT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XBiotech
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Ticker
$XBIT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
92
Website
XBiotech Metrics
BasicAdvanced
$100M
-
-$1.08
1.41
-
Price and volume
Market cap
$100M
Beta
1.41
52-week high
$9.96
52-week low
$2.94
Average daily volume
53K
Financial strength
Current ratio
11.57
Quick ratio
11.505
Total debt to equity
5.205
Interest coverage (TTM)
-70.17%
Management effectiveness
Return on assets (TTM)
-12.03%
Return on equity (TTM)
-15.75%
Valuation
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-3.432
Growth
Earnings per share change (TTM)
41.57%
3-year earnings per share growth (CAGR)
35.78%
XBiotech Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
XBiotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
XBiotech News
AllArticlesVideos
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Accesswire·2 weeks ago
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Accesswire·2 weeks ago
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for XBiotech stock?
XBiotech (XBIT) has a market cap of $100M as of March 14, 2025.
What is the P/E ratio for XBiotech stock?
The price to earnings (P/E) ratio for XBiotech (XBIT) stock is 0 as of March 14, 2025.
Does XBiotech stock pay dividends?
No, XBiotech (XBIT) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next XBiotech dividend payment date?
XBiotech (XBIT) stock does not pay dividends to its shareholders.
What is the beta indicator for XBiotech?
XBiotech (XBIT) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.